Josh Distler and Victoria Niklas (Oak Hill Bio)
February 1, 2022 06:48 AM EST
Startups

Take­da spins PhII rare dis­ease pro­grams in­to new start­up — send­ing 2 ex­ecs and some cash to get things go­ing

Amber Tong

The club of biotech star­tups de­vel­op­ing pro­grams spun out from Take­da keeps ad­mit­ting new mem­bers.

Oak Hill Bio is the lat­est to de­but, launch­ing not …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times